Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTD2 plus fluoropyrimidine and platinum as first-line treatment for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20252706Phase 3Active
- Sponsor
- 成都华昊中天药业有限公司/ 北京华昊中天生物医药股份有限公司
- Start
- Sep 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of utidelone in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by 成都华昊中天药业有限公司/ 北京华昊中天生物医药股份有限公司. Started Sep 2025; status: active.
02
Drugs
utidelone
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20252706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252706.